Esperovax, a developer of oral mRNA biologics, and Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, Thursday announced a partnership to develop circular RNAs for a variety of therapeutic applications.
Initially, Ginkgo and Esperovax would work to develop circRNAs harboring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.
